Rakez Kayed

List of Publications by Year in Descending Order

166 papers	22,685 citations	56 h-index	150 g-index
200 ext. papers	25,641 ext. citations	7.7 avg, IF	6.7 L-index

#	Paper	IF	Citations
166	A tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer's disease.. *Cellular and Molecular Life Sciences*, **2022**, 79, 222	10.3	2
165	Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer's disease.. *Journal of Biological Chemistry*, **2022**, 101766	5.4	1
164	Amyloid , Tau, and Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.. *Progress in Neurobiology*, **2022**, 102270	10.9	3
163	Post-translational Modifications of the p53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature.. *Frontiers in Aging Neuroscience*, **2022**, 14, 835288	5.3	2
162	Quantification and targeting of elusive neurotoxic amyloid oligomers.. *Cell Reports Medicine*, **2022**, 3, 100636	18	0
161	Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes.. *Frontiers in Molecular Neuroscience*, **2021**, 14, 742790	6.1	1
160	Dynamic interactions and Ca-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. *Nature Communications*, **2021**, 12, 6292	17.4	0
159	Early alterations of neurovascular unit in the retina in mouse models of tauopathy. *Acta Neuropathologica Communications*, **2021**, 9, 51	7.3	4
158	Tau induces formation of synuclein filaments with distinct molecular conformations. *Biochemical and Biophysical Research Communications*, **2021**, 554, 145-150	3.4	3
157	Alzheimer's disease brain-derived extracellular vesicles spread tau pathology in interneurons. *Brain*, **2021**, 144, 288-309	11.2	33
156	Curcumin as Scaffold for Drug Discovery against Neurodegenerative Diseases. *Biomedicines*, **2021**, 9,	4.8	2
155	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. *Chemical Reviews*, **2021**, 121, 2545-2647	68.1	128
154	Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia. *Cell Reports*, **2021**, 36, 109419	10.6	12
153	Infectious etiology and amyloidosis in Alzheimer's disease: The puzzle continues. *Journal of Biological Chemistry*, **2021**, 297, 100936	5.4	2
152	Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers. *Aging Cell*, **2021**, 20, e13455	9.9	2
151	Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC-induced neurons with the V337M MAPT mutation.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e051471	1.2	
150	AD- and PSP-specific brain-derived tau oligomers engage synapses with different dynamic.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e054394	1.2	

149	Elucidating the pathogenic mechanisms of AD brain-derived, tau-containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons. *Alzheimer's and Dementia*, **2020**, 16, e037316	1.2	0
148	Differential dynamics of A and tau oligomer synaptic binding may suggest diverse therapeutic targets for early vs. late Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e038045	1.2	
147	Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology. *Alzheimer's and Dementia*, **2020**, 16, e039815	1.2	
146	Soluble endogenous oligomeric -synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. *Journal of Parkinson's Disease*, **2020**, 10, 791-818	5.3	23
145	Polymorphic -Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. *Molecular Neurobiology*, **2020**, 57, 2741-2765	6.2	12
144	Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. *Cell Death and Disease*, **2020**, 11, 314	9.8	31
143	Advances and considerations in AD tau-targeted immunotherapy. *Neurobiology of Disease*, **2020**, 134, 104707	7.5	34
142	TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. *Neurobiology of Disease*, **2020**, 146, 105130	7.5	19
141	Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer's Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers. *Journal of Alzheimer's Disease*, **2020**, 78, 1661-1678	4.3	7
140	P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease. *Acta Neuropathologica Communications*, **2020**, 8, 132	7.3	28
139	Modulating disease-relevant tau oligomeric strains by small molecules. *Journal of Biological Chemistry*, **2020**, 295, 14807-14825	5.4	12
138	RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. *Nature Communications*, **2020**, 11, 4305	17.4	24
137	Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. *Progress in Neurobiology*, **2020**, 184, 101716	10.9	49
136	Tau oligomers mediate aggregation of RNA-binding proteins Musashi1 and Musashi2 inducing Lamin alteration. *Aging Cell*, **2019**, 18, e13035	9.9	15
135	Neurotoxic tau oligomers after single versus repetitive mild traumatic brain injury. *Brain Communications*, **2019**, 1, fcz004	4.5	14
134	Tau Interacts with the C-Terminal Region of -Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations. *Biochemistry*, **2019**, 58, 2814-2821	3.2	25
133	Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies. *Molecular Neurobiology*, **2019**, 56, 3341-3355	6.2	16
132	P4-520: TAU OLIGOMERS MEDIATE AGGREGATION OF RNA-BINDING PROTEINS MUSASHI1- AND MUSASHI2-INDUCING NUCLEAR MEMBRANE ALTERATION IN ALZHEIMER'S DISEASE **2019**, 15, P1513-P1513		

131	NLRP3 inflammasome activation drives tau pathology. *Nature*, **2019**, 575, 669-673	50.4	375
130	Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. *Scientific Reports*, **2019**, 9, 19011	4.9	24
129	Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 89-102	6	19
128	Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. *Npj Vaccines*, **2018**, 3, 9	9.5	33
127	Azure C Targets and Modulates Toxic Tau Oligomers. *ACS Chemical Neuroscience*, **2018**, 9, 1317-1326	5.7	23
126	□Synuclein Oligomers Induce a Unique Toxic Tau Strain. *Biological Psychiatry*, **2018**, 84, 499-508	7.9	40
125	Tau oligomers mediate □synuclein toxicity and can be targeted by immunotherapy. *Molecular Neurodegeneration*, **2018**, 13, 13	19	43
124	Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides. *Chemical Communications*, **2018**, 54, 10120-10123	5.8	16
123	Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. *Protein Science*, **2018**, 27, 1901-1909	6.3	50
122	Preparation and Characterization of Tau Oligomer Strains. *Methods in Molecular Biology*, **2018**, 1779, 113-146	1.4	7
121	O2-02-06: PROPAGATION AND DIVERSE EFFECTS OF DISEASE-SPECIFIC PRION-LIKE TAU OLIGOMERIC STRAINS **2018**, 14, P612-P612		
120	P1-021: TOXICITY AND PROPAGATION OF TBI BRAIN-DERIVED SOLUBLE TAU STRAINS **2018**, 14, P273-P273		
119	O2-01-03: SELECTED MICRO RNAS FROM NEURAL STEM CELL□DERIVED EXOSOMES INCREASE SYNAPTIC RESILIENCE TO TAU AND A□OLIGOMERS **2018**, 14, P609-P609		
118	P3-170: INCREASED SYNAPTIC SENSITIVITY TO A□AND TAU OLIGOMERS IN THE AGING CNS AS A FUNCTION OF DECREASING NEURAL STEM CELLS **2018**, 14, P1133-P1133		
117	P3-167: INHIBITION OF PHOSPHOLIPASE D1 AS A THERAPEUTIC IN AD-RELATED MEMORY DEFICITS **2018**, 14, P1131-P1132		
116	P4-023: TAU IMMUNOTHERAPY FOR ALPHA-SYNUCLEINOPATHY **2018**, 14, P1442-P1442		
115	P1-025: EXOSOMES CONTAINING SPECIFIC TAU OLIGOMER FORMATIONS ACCELERATE PATHOLOGICAL TAU PHOSPHORYLATION IN C57BL/6 MICE **2018**, 14, P275-P275		1
114	O5-05-06: EVALUATING TAU OLIGOMERS PASSIVE IMMUNOTHERAPY USING AGED TRANSGENIC ANIMALS OF TAUOPATHY **2018**, 14, P1657-P1657		

113	O4-05-04: Tau Immunotherapy for Alpha-Synucleinopathy **2018**, 14, P1412-P1412		
112	AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation **2018**, 59, 4670-4682		9
111	Formation of Toxic Oligomeric Assemblies of RNA-binding Protein: Musashi in Alzheimer's disease. *Acta Neuropathologica Communications*, **2018**, 6, 113	7.3	17
110	iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. *Neuron*, **2017**, 94, 278-293.e9	13.9	445
109	Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. *Journal of Alzheimer's Disease*, **2017**, 58, 471-478	4.3	12
108	Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4648-E4657	11.5	34
107	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2017**, 4, 226-235	5.3	40
106	Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush. *American Journal of Pathology*, **2017**, 187, 352-365	5.8	19
105	Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. *Methods in Molecular Biology*, **2017**, 1523, 141-157	1.4	24
104	Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies **2017**, 8, 257-266		55
103	[F4□07□03]: TAU OLIGOMERIC STRAINS IN SYNUCLEINOPATHIES **2017**, 13, P1219-P1220		
102	[P4□456]: TAU AND P53 IN ALZHEIMER'S DISEASE **2017**, 13, P1505		1
101	[P4□406]: INVESTIGATING THE POTENTIAL OF NOVEL CURCUMIN DERIVATIVES IN TARGETING AND MODULATING TOXIC TAU OLIGOMERIC STRAINS **2017**, 13, P1486		
100	Oligomer Formation and Cross-Seeding: The New Frontier. *Israel Journal of Chemistry*, **2017**, 57, 665-673	3.4	5
99	[O1□07□03]: SYNAPTIC RESILIENCE TO TAU AND AMYLOID BETA OLIGOMERS INDUCED BY NEURAL STEM CELL-DERIVED EXOSOMES **2017**, 13, P205		
98	[P4□451]: TBI AND AD: SIMILAR TAU-INDUCED NEURODEGENERATION? **2017**, 13, P1503-P1504		
97	Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. *Journal of Alzheimer's Disease*, **2017**, 55, 1083-1099	4.3	87
96	A□Amyloid Pathology Affects the Hearts of Patients□With□Alzheimer's Disease: Mind□the Heart. *Journal of the American College of Cardiology*, **2016**, 68, 2395-2407	15.1	81

95	Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. *Journal of Neurotrauma*, **2016**, 33, 2034-2043	5.4	57
94	Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. *Neurobiology of Disease*, **2016**, 87, 19-28	7.5	39
93	Therapeutic Approaches Targeting Pathological Tau Aggregates. *Current Pharmaceutical Design*, **2016**, 22, 4028-39	3.3	9
92	The Role of Amyloid-□Oligomers in Toxicity, Propagation, and Immunotherapy. *EBioMedicine*, **2016**, 6, 42-49	8.8	365
91	Potential mechanisms and implications for the formation of tau oligomeric strains. *Critical Reviews in Biochemistry and Molecular Biology*, **2016**, 51, 482-496	8.7	40
90	Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer□s disease mouse model. *Journal of Neuroscience*, **2015**, 35, 4857-68	6.6	99
89	Antibody against Small Aggregated Peptide Specifically Recognizes Toxic A□42 Oligomers in Alzheimer□s Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1981-9	5.7	14
88	Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. *Neurobiology of Disease*, **2015**, 82, 540-551	7.5	48
87	The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. *Aging Cell*, **2015**, 14, 715-24	9.9	51
86	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. *Biological Psychiatry*, **2015**, 78, 672-83	7.9	109
85	A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. *ELife*, **2015**, 4,	8.9	23
84	Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes. *ELife*, **2015**, 4,	8.9	12
83	Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. *Biochemical Pharmacology*, **2014**, 88, 468-78	6	84
82	Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. *Journal of Neuroscience*, **2014**, 34, 4260-72	6.6	193
81	Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. *ACS Chemical Neuroscience*, **2014**, 5, 752-69	5.7	51
80	TDP-43 Phosphorylation by casein kinase I□promotes oligomerization and enhances toxicity in vivo. *Human Molecular Genetics*, **2014**, 23, 1025-35	5.6	65
79	Amyloid-□oligomers as a template for secondary amyloidosis in Alzheimer□s disease. *Neurobiology of Disease*, **2014**, 71, 14-23	7.5	46
78	P1-122: OLIGOMERS OF A-SYNUCLEIN CROSS-SEED TAU AND EXTEND LIFETIME OF TAU TOXIC CONFORMATION **2014**, 10, P345-P345		

77	P3-066: TDP-43 HYBRID OLIGOMERS IN ALZHEIMER'S DISEASE **2014**, 10, P651-P651		
76	O1-08-06: TAU OLIGOMERS DERIVED FROM TRAUMATIC BRAIN INJURY CAUSE TOXICITY AND COGNITIVE IMPAIRMENT IN HTAU MICE **2014**, 10, P146-P146		
75	P4-215: TAU OLIGOMER-SPECIFIC ANTIBODIES IN INTRAVENOUS IMMUNOGLOBULINS (IVIGS): POTENTIAL THERAPEUTIC SIGNIFICANCE IN ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE TAUOPATHIES **2014**, 10, P866-P867		
74	P2-071: PATHOLOGICAL TAU SPECIES ABROGATE NASCENT PROTEIN PRODUCTION BY ASSOCIATING WITH THE RIBOSOMAL COMPLEX: IMPLICATIONS OF A NOVEL TAU FUNCTION AND ITS PATHOGENIC LINK TO MEMORY IMPAIRMENT **2014**, 10, P495-P496		
73	O5-04-01: DIFFERENT OLIGOMERIC TAU STRAINS ARE DETECTED WITH NOVEL ANTI-TAU OLIGOMER-SPECIFIC ANTIBODIES **2014**, 10, P297-P297		
72	Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S97-S111	4.3	116
71	The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. *Acta Neuropathologica Communications*, **2014**, 2, 56	7.3	50
70	Characterization of tau oligomeric seeds in progressive supranuclear palsy. *Acta Neuropathologica Communications*, **2014**, 2, 73	7.3	60
69	Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?. *ImmunoTargets and Therapy*, **2014**, 3, 19-28	9	9
68	Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. *Journal of Biological Chemistry*, **2013**, 288, 1856-70	5.4	333
67	Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. *Biochemical and Biophysical Research Communications*, **2013**, 430, 963-8	3.4	58
66	Tau aggregates as immunotherapeutic targets. *Frontiers in Bioscience - Scholar*, **2013**, 5, 426-38	2.4	27
65	Molecular mechanisms of amyloid oligomers toxicity. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S67-78	4.3	235
64	Design of metastable β-sheet oligomers from natively unstructured peptide. *ACS Chemical Neuroscience*, **2013**, 4, 1520-3	5.7	14
63	Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. *Journal of Biological Chemistry*, **2013**, 288, 17042-17050	5.4	91
62	Formation and propagation of tau oligomeric seeds. *Frontiers in Neurology*, **2013**, 4, 93	4.1	75
61	Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. *Journal of Clinical Investigation*, **2013**, 123, 4158-69	15.9	169
60	Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe. *American Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 3, 102-17	2.2	3

59	O4-06-01: Specific clearance of tau oligomers by passive immunization **2012**, 8, P624-P625		
58	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. *Scientific Reports*, **2012**, 2, 700	4.9	305
57	Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. *Molecular Neurodegeneration*, **2012**, 7, 37	19	30
56	Differential activation of the ER stress factor XBP1 by oligomeric assemblies. *Neurochemical Research*, **2012**, 37, 1707-17	4.6	34
55	-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. *Journal of Neurochemistry*, **2012**, 120, 440-52	6	77
54	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. *FASEB Journal*, **2012**, 26, 1946-59	0.9	309
53	Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. *Frontiers in Neurology*, **2012**, 3, 5	4.1	14
52	Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. *Journal of the American Academy of Dermatology*, **2011**, 65, 1023-31	4.5	10
51	Amyloid- annular protofibrils evade fibrillar fate in Alzheimer disease brain. *Journal of Biological Chemistry*, **2011**, 286, 22122-30	5.4	103
50	Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. *Journal of Central Nervous System Disease*, **2011**, 3, 67-73	4.4	6
49	Astrocytes contain amyloid- annular protofibrils in Alzheimer's disease brains. *FEBS Letters*, **2011**, 585, 3052-7	3.8	31
48	Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. *Molecular Neurodegeneration*, **2011**, 6, 39	19	338
47	Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. *Experimental Dermatology*, **2010**, 19, 904-11	4	9
46	Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid- resulting in neurodegeneration. *Journal of Alzheimer's Disease*, **2010**, 22, 959-70	4.3	21
45	Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. *Journal of Neuroscience*, **2010**, 30, 2442-53	6.6	149
44	Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. *Hum Vaccin*, **2010**, 6, 931-5		31
43	New vaccine development for chronic brain disease. *Neuropsychopharmacology*, **2010**, 35, 354	8.7	4
42	Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. *Journal of Alzheimer's Disease*, **2010**, 20, 637-46	4.3	54

41	Preparation and characterization of neurotoxic tau oligomers. *Biochemistry*, **2010**, 49, 10039-41	3.2	254
40	Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. *Journal of Neuroscience Research*, **2010**, 88, 2923-32	4.4	75
39	Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar A□oligomers. *Molecular Neurodegeneration*, **2010**, 5, 57	19	110
38	A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. *Acta Neuropathologica*, **2009**, 118, 505-17	14.3	37
37	Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. *Current Opinion in Immunology*, **2009**, 21, 359-63	7.8	44
36	Poloxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. *Journal of Molecular Biology*, **2009**, 391, 577-85	6.5	26
35	Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. *Journal of Biological Chemistry*, **2009**, 284, 4230-7	5.4	255
34	Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. *PLoS ONE*, **2009**, 4, e5562	3.7	83
33	Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. *International Journal of Alzheimer's Disease*, **2009**, 2009,	3.7	16
32	Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. *Aging Cell*, **2008**, 7, 824-35	9.9	75
31	CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. *Journal of Experimental Medicine*, **2008**, 205, 1593-9	16.6	20
30	Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin. *Molecular Neurodegeneration*, **2008**, 3, 16	19	42
29	Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Molecular Neurodegeneration*, **2007**, 2, 18	19	544
28	Pore-forming proteins share structural and functional homology with amyloid oligomers. *NeuroMolecular Medicine*, **2007**, 9, 270-5	4.6	61
27	Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 5995-6000	11.5	66
26	Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. *Diabetes*, **2007**, 56, 1324-32	0.9	152
25	Age-dependent axonal degeneration in an Alzheimer mouse model. *Neurobiology of Aging*, **2007**, 28, 1689-99	5.6	91
24	Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. *Journal of Biological Chemistry*, **2007**, 282, 10311-24	5.4	547

23	ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. *Journal of Biological Chemistry*, **2006**, 281, 20315-25	5.4	138
22	Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. *Journal of General Physiology*, **2006**, 128, 637-47	3.4	177
21	Conformation-dependent anti-amyloid oligomer antibodies. *Methods in Enzymology*, **2006**, 413, 326-44	1.7	128
20	Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. *Neurology*, **2006**, 66, S74-8	6.5	293
19	A specific amyloid-beta protein assembly in the brain impairs memory. *Nature*, **2006**, 440, 352-7	50.4	2406
18	Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. *Journal of Clinical Investigation*, **2006**, 116, 378-85	15.9	135
17	Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *Journal of Biological Chemistry*, **2005**, 280, 5892-901	5.4	1668
16	Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *Journal of Biological Chemistry*, **2005**, 280, 17294-300	5.4	761
15	Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. *Molecular and Cellular Neurosciences*, **2005**, 28, 496-508	4.8	6
14	Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. *Brain Research*, **2005**, 1031, 222-8	3.7	102
13	Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. *Brain Research*, **2005**, 1045, 224-8	3.7	17
12	Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13592-7	11.5	93
11	LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. *Journal of Lipid Research*, **2005**, 46, 115-22	6.3	38
10	Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10132-6	11.5	222
9	Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. *Journal of Biological Chemistry*, **2004**, 279, 46363-6	5.4	695
8	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*, **2003**, 300, 486-9	33.3	3389
7	Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron*, **2003**, 39, 409-21	13.9	3031
6	The influence of the carboxyl terminus of the Alzheimer Abeta peptide on its conformation, aggregation, and neurotoxic properties. *NeuroMolecular Medicine*, **2002**, 1, 81-94	4.6	14

5	Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. *Journal of Biological Chemistry*, **2002**, 277, 40810-5	5.4	325
4	Isolation, structural, and functional characterization of an apoptosis-inducing L-amino acid oxidase from leaf-nosed viper (Eristocophis macmahoni) snake venom. *Archives of Biochemistry and Biophysics*, **2000**, 384, 216-26	4.1	81
3	Rational design, conformational studies and bioactivity of highly potent conformationally constrained calcitonin analogues. *FEBS Journal*, **1999**, 265, 606-18		26
2	Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. *Journal of Molecular Biology*, **1999**, 287, 781-96	6.5	326
1	Tau modulates mRNA transcription, alternative polyadenylation profiles of hnRNPs, chromatin remodeling and spliceosome complexes		1